《新股消息》內地安能物流遞上市申請 傳籌5億美元
內地貨運物流供應商安能物流提交主板上市申請,聯席保薦人為摩根大通及中金公司。早前外電報道指,安能物流目標來港上市,集資約5億美元。
初步招股文件顯示,安能物流2020年度貨運總量達到1,020萬噸,於中國各地擁有147家自營分撥中心,與約2.64萬名貨運合作商及代理商合作,網點覆蓋約96%的縣城和鄉鎮。安能物流去年收入達70.81億元人民幣,按年增長32.6%,期內扭虧錄得利潤2.18億元人民幣,對比2019年為虧損2.14億元人民幣。
安能物流上市前股東包括鼎暉投資、新創建(00659.HK)、中國平安(02318.HK)、凱雷集團、大灣區共同家園發展基金、高盛及伊利(600877.SH)等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.